News Column

Investigators at University of Utah Describe Findings in Ischemic Heart Disease (Cell therapy, 3D culture systems and tissue engineering for cardiac...

July 2, 2014



Investigators at University of Utah Describe Findings in Ischemic Heart Disease (Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Ischemic Heart Disease. According to news reporting originating in Salt Lake City, Utah, by NewsRx journalists, research stated, "Ischemic Heart Disease (IHD) still represents the 'Number One Killer' worldwide accounting for the death of numerous patients. However the capacity for self-regeneration of the adult heart is very limited and the loss of cardiomyocytes in the infarcted heart leads to continuous adverse cardiac-remodeling which often leads to heart-failure (HF)."

The news reporters obtained a quote from the research from the University of Utah, "The concept of regenerative medicine comprising cell-based therapies, bio-engineering technologies and hybrid solutions has been proposed as a promising next-generation approach to address IHD and HF. Numerous strategies are under investigation evaluating the potential of regenerative medicine on the failing myocardium including classical cell-therapy concepts, three-dimensional culture techniques and tissue-engineering approaches. While most of these regenerative strategies have shown great potential in experimental studies, the translation into a clinical setting has either been limited or too rapid leaving many key questions unanswered."

According to the news reporters, the research concluded: "This review summarizes the current state-of-the-art, important challenges and future research directions as to regenerative approaches addressing IHD and resulting HF."

For more information on this research see: Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration. Advanced Drug Delivery Reviews, 2014;69():254-269. Advanced Drug Delivery Reviews can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Advanced Drug Delivery Reviews - www.elsevier.com/wps/product/cws_home/505508)

Our news correspondents report that additional information may be obtained by contacting M.Y. Emmert, University of Utah, Dept. of Bioengn, Salt Lake City, UT 84112, United States. Additional authors for this research include R.W. Hitchcock and S.P. Hoerstrup (see also Ischemic Heart Disease).

Keywords for this news article include: Utah, Biotechnology, Tissue Engineering, Biomedical Engineering, Biomedicine, Cardiology, Cell Therapy, United States, Heart Failure, Salt Lake City, Bioengineering, Biological Therapy, Regenerative Medicine, Ischemic Heart Disease, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters